Trial reportFertility and sterility2013
Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy.
Trial report in Fertility and sterility, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02467231 (Ovarian Reserve After Cancer), which is not on this map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ovarian Reserve After Cancer: Longitudinal Effects A Multicenter Prospective Cohort Study by the Oncofertility Consortium
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.Human reproduction update · 2022Pooled it
- Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review.Reproductive biology and endocrinology : RB&E · 2014Pooled it
- The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.European journal of cancer (Oxford, England : 1990) · 2017Trial
- Ethical considerations and management strategies for fertility preservation in women of reproductive age with malignant tumors: Chinese practices and perspectives.Frontiers in endocrinology · 2026Review
- [Fertility management in breast cancer patients: current strategies and research advances].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Does the Type of Cancer Influence Anti-Müllerian Hormone Levels in Women of Reproductive Age? A Cross-Sectional Study.Biomedicines · 2025Article
- Anti-Mullerian Hormone and conception timing as predictors of live births in cancer patients using fertility preservation: a systematic review.Frontiers in oncology · 2025Review
- Age and serum anti-Müllerian hormone levels as predictors of time to return of menses after chemotherapy.Reproduction & fertility · 2025Article
- Ovarian Insufficiency and Fertility Preservation During and After Childhood Cancer Treatment.Journal of adolescent and young adult oncology · 2024Review
- Oocyte collection and outcome following oncologic treatment: a retrospective multicentre study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Review
- Fertility Potential and Gonadal Function in Survivors of Reduced-Intensity Hematopoietic Stem Cell Transplantation.Transplantation and cellular therapy · 2024Article
- Female cancer survivors: sexual function, psychological distress, and remaining fertility.Journal of assisted reproduction and genetics · 2024Article
- A New Model Including AMH Cut-off Levels to Predict Post-treatment Ovarian Function in Early Breast Cancer: A Prospective Cohort Study.Archives of Iranian medicine · 2024Article
- Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
- Reproductive Considerations for Patients with Early-Onset Breast Cancer.Current breast cancer reports · 2022Article
- Fertility after Cancer: Risks and Successes.Cancers · 2022Review
- Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors.Fertility and sterility · 2022Article
- Factors Associated with Unplanned Pregnancy Among Cancer Survivors.Journal of women's health (2002) · 2022Article
- Investigating the Clinical Utility of the Anti-Mullerian Hormone Testing for the Prediction of Age at Menopause and Assessment of Functional Ovarian Reserve: A Practical Approach and Recent Updates.Aging and disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo identify factors associated with ovarian reserve impairment during and immediately after chemotherapy.
designProspective cohort study.
settingFour university hospitals. PATIENT(S): Forty-six adolescent and young adult women with a new diagnosis of cancer requiring chemotherapy. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Measurements of ovarian reserve via levels of serum follicle-stimulating hormone, luteinizing hormone, estradiol, inhibin B, and antimüllerian hormone (AMH) as well as antral follicle counts and mean ovarian volume at 3-month intervals. RESULT(S): Changes in ovarian reserve were quantified for both the acute impact of treatment using linear regression and the longitudinal recovery after therapy using mixed-effects models adjusted for baseline ovarian reserve, use of alkylating agent, and hormone use. The women had at least one pretreatment and two posttreatment study visits (mean follow-up interval: 12 months). All measures of ovarian reserve demonstrated statistically significant changes during chemotherapy. Alkylating agent exposure and baseline ovarian reserve were acutely associated with the magnitude of impairment, and pretreatment AMH levels were associated with the rate of recovery of AMH after treatment. In adjusted models, participants with a pretreatment AMH level > 2 ng/mL recovered at a rate of 11.9% per month after chemotherapy, whereas participants with pretreatment AMH levels ≤ 2 ng/mL recovered at a rate of 2.6% per month after therapy. CONCLUSION(S): Baseline ovarian reserve and alkylating agent exposure effect the magnitude of acute changes in ovarian reserve from chemotherapy. The rate of recovery of AMH is impacted by pretreatment levels. This should be considered during pretreatment fertility preservation counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.